<DOC>
	<DOCNO>NCT00198302</DOCNO>
	<brief_summary>Hospitalized patient least 18 year age , Staphylococcus aureus bacteremia ( SAB ) enrol study receive one dose Aurexis® intravenously Study Day 1 , follow Study Day 57 . Aurexis humanize monoclonal antibody design combat Staphylococcus aureus . The purpose study assess safety pharmacokinetics standard antibiotic therapy , plus Aurexis Placebo treatment ( SAB ) . Additionally , certain test measurement conduct preliminarily determine Aurexis demonstrate benefit patient .</brief_summary>
	<brief_title>Clinical Trial Comparing Safety Pharmacokinetics Standard Antibiotic Therapy , Plus Aurexis® Placebo , Treatment Staphylococcus Aureus Bacteremia ( SAB )</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>Male female , age ≥ 18 year old Informed consent obtain subject legal guardian Willing practice reliable birth control measure study period Diagnosis SAB , evidence clinical symptom one positive blood culture obtain ≤ 72 hour prior initiation study drug infusion Pregnant nursing female Polymicrobial bacteremia Diagnosis septic shock ( refer APPENDIX B ) Neutropenia ( absolute neutrophil count &lt; 500/mm³ ) Undergoing type dialysis expect start dialysis within 30 day Moribund clinical condition high likelihood death within 72 hour randomization Received investigational drug within 30 day study entry Considered unlikely comply study procedure return schedule posttreatment evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>staphylococcus aureus</keyword>
	<keyword>bacteremia</keyword>
	<keyword>sepsis</keyword>
</DOC>